Prognostic factor of serum carcinoembryonic antigen in colorectal cancer patients: a follow up study

Taha HT Al-Saigh; Shatha A Abdulmawjood; Faris A Ahmed

doi:10.32947/ajps.v21i3.791

Authors

Taha HT Al-Saigh Ninevah College of Medicine, University of Nineveh, Mosul
Shatha A Abdulmawjood Ninevah College of Medicine, University of Nineveh, Mosul
Faris A Ahmed College of Pharmacy, University of Uruk, Baghdad

DOI:

https://doi.org/10.32947/ajps.v21i3.791

Abstract

Colorectal cancer is a serious cancer with high mortality. Most of the recurrence usually occurred within two years after surgery. This study was conducted in Nineveh Medical Center and Al-Jammhorri Hospital to evaluate colorectal cancer patients in a follow up study for

two years. Serum carcinoembryonic antigen, colonoscopy, ultrasound of the abdomen, and chest X rays were used for evaluation. One hundred and ninety-four patients with colorectal cancer were included in the study. The patients were diagnosed colorectal adenocarcinomas by histopathology and staged according to Duke’s classification. The patients were undergone surgical removal of the cancer. Chemotherapy was started to the patient after two weeks of the surgery. Blood samples were taken one week before and one week after surgery. Other blood samples were taken after chemotherapy and then every six months for two years. The blood samples were analyzed for serum carcinoembryonic antigen. The patients were also checked by colonoscopy, ultrasound for abdomen, and chest X ray every six months. Serum carcinoembryonic antigen in colorectal patients was higher than 5 ng/mL and decreased significantly after surgery but still higher than 5 ng/mL. After chemotherapy serum decreased significantly compared with that after surgery. During the two-year period serum carcinoembryonic antigen was not significantly different from that in patients after chemotherapy. Twenty-one patients died after two years of the study Serum carcinoembryonic antigen in the dead patients was much significantly higher than 5 ng/mL before surgery and decreased significantly after operation and after chemotherapy but still higher than 5 ng/mL. In conclusion, colorectal cancer is a significant disease in Iraq. The mortality rate is high due to lack of education of the community to that disease. Carcinoembryonic antigen marker is still acceptable test but should be used with other clinical assessments

References

- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar; 65: 87-108. DOI: https://doi.org/10.3322/caac.21262

- https://www.cancer.org/research/cancer-facts-statistics/colorectal-cancer-facts-figures.html. Accessed April, 2017.

- Binefa G, Rodríguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014 Jun; 20(22): 6786-808. DOI: https://doi.org/10.3748/wjg.v20.i22.6786

- American Cancer Society, Colorectal Cancer Facts & Figures 2014–2016, American Cancer Society, Atlanta, Ga, USA, 2014.

- Godhi S, Godhi A, Bhat R, Saluja S. Colorectal cancer: postoperative follow-up and surveillance. Indian J Surg. 2017 Jun; 79(3): 234–7. DOI: https://doi.org/10.1007/s12262-017-1610-6

- Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum. 1994 Mar; 37(3): 272-7. DOI: https://doi.org/10.1007/BF02048166

- Locker GY, S. Hamilton S, Harris J, Jessup MJ, Kemeny N, Macdonald JS, et al., ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006 Nov; 24 (33): 5313–27. DOI: https://doi.org/10.1200/JCO.2006.08.2644

- Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers and Prev 2007; 16 (10): 1935–53. DOI: https://doi.org/10.1158/1055-9965.EPI-06-0994

- Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful. Clin Chem 2001; 47(4): 624-30. DOI: https://doi.org/10.1093/clinchem/47.4.624

- Wang JY, Lu CY, Chu KS, Ma CJ, Wu DC, Tsai HL, et al. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 2007; 39(4): 245-50. DOI: https://doi.org/10.1159/000101952

- Abe S, Kawai K, Ishihara S, Nozawa H, Hata K, Kiyomatsu T, et al. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after Ro resection. J Surg Res 2016 Oct; 205(2): 384-92. DOI: https://doi.org/10.1016/j.jss.2016.06.078

- Baqar AR, Wilkins S, Staples M, Angus Lee CH, Oliva K, McMurrick P. The role of preoperative CEA in the management of colorectal cancer: A cohort study from two cancer centres. Int J Surg. 2019 Apr; 64: 10-15. DOI: https://doi.org/10.1016/j.ijsu.2019.02.014

- Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005; 23(4): 338-51. DOI: https://doi.org/10.1081/CNV-58878

- Sun Z, Wang F, Zhou Q, Yang S, Sun X, Wang G, et al. Pre-operative to post-operative serum carcinoembryonic antigen ratio is a prognostic indicator in colorectal cancer. Oncotarget. 2017 May; 8(33): 54672-82. DOI: https://doi.org/10.18632/oncotarget.17931

- Gunawardene A, Larsen P, Shekouh A, Dennett E. Pre-operative carcinoembryonic antigen predicts survival following colorectal cancer surgery with curative intent. ANZ J Surg 2018 Dec; 88(12): 1311-15. DOI: https://doi.org/10.1111/ans.14723

- Konishi T, Shimada Y, Hsu M, Tufts L, Rosa Jimenez-Rodriguez R, Cercek A, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol 2018 Mar; 4(3): 309-315. DOI: https://doi.org/10.1001/jamaoncol.2017.4420

- Gonzalez-Pons M, Cruz-Correa M. Colorectal cancer biomarkers: where are we now? Biomed Res Int. 2015; 2015: 149014. DOI: https://doi.org/10.1155/2015/149014

- Aakif M, Balfe P, Elfaedy O, Awan FN, Pretorius F, Leonardo Silvio L, et al. Study on colorectal cancer presentation, treatment and follow-up. Int J Colorectal Dis 2016 Jul; 31(7): 1361-3. DOI: https://doi.org/10.1007/s00384-015-2479-0

- Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014 Apr 26; 383(9927): 1490-1502. DOI: https://doi.org/10.1016/S0140-6736(13)61649-9

- Hara M, Kanemitsu Y, Hirai T, Komori K, Kato T. Negative serum carcino-embryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study. Dis Colon Rectum. 2008 Nov; 51(11): 1675-80. DOI: https://doi.org/10.1007/s10350-008-9406-1

- Weinberg BA, Marshall JL, Salem ME. The growing challenge of young adults with colorectal cancer. Oncology (Williston Park). 2017 May; 31(5): 381-9.

- Al-Siagh TH, Al-bayati Sh A, Abdulmawjood ShA, Ahmed FA. Descriptive study of colorectal cancer in Iraq, 1999-2016. Ann coll Med Mosul 2019;41(1):81-85. DOI: https://doi.org/10.33899/mmed.2019.161330

- Grundmann RT, Meyer F. Gender-specific influences on incidence, screening, treatment, and outcome of colorectal cancer. Zentralbl Chir. 2013 Aug; 138(4):434-41. DOI: https://doi.org/10.1055/s-0033-1350631

- Yang Y, Wang G, He J, Ren S, Wu F, Zhang J, et al. Gender differences in colorectal cancer survival: A meta-analysis. Int J Cancer 2017 Nov; 141(10): 1942-49. DOI: https://doi.org/10.1002/ijc.30827